Atlantic Healthcare plc, a gastrointestinal focused pharmaceutical company, has appointed John Temperato as U.S. president and chief operating officer, to lead the commercialization program of alicaforsen in the U.S. Atlantic Healthcare is developing alicaforsen for the treatment of inflammatory bowel disease with results from the Phase III trial in the treatment of orphan-designated IBD pouchitis expected in 1Q19. Pouchitis is a rare and serious form of IBD for which there is no approved the...